OakChart

111 Inc ADR

YIHealthcare·Medical Distribution·China·Nano·NASD·Nov 10 • 3:59 PM ET

2.950.00 (0.00%)
2026-11-11 14:22 CET
Market cap
15.30 USD m
Revenue, TTM
1,495.96 USD m
Net income, TTM
-15.20 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-1.73
P/E
-
Compare

Price

YI against its 20, 50 and 200-day averages
2050200earnings
3.004.005.006.007.00100K201KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26YIclose 2.9520-day 3.0150-day 3.23200-day 5.002.95

73.6% under 11.17 on 30 Jan 2026. Last 15 sessions, 16.8% high to low

Profile

YI
52-week range, 5% of the way up
2.4811.17

111, Inc. Is a holding company, which engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.

Employees1063
IPOSep 12, 2018
Beta0.74
ATR, 14d0.15
Rel volume0.00
Short float0.26%
Insider own1.82%
Inst own2.23%

Snapshot

6 groups

Valuation

Index-
Market Cap15.31M
Enterprise Value138.61M
Income-15.20M
Sales1.50B
Book/sh-13.02
Cash/sh10.82
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees1063
IPOSep 12, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S0.01
P/B-
P/C0.27
P/FCF-
EV/EBITDA-
EV/Sales0.09
Quick Ratio0.51
Current Ratio1.07
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.73
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y47.72% 33.28%
Sales past 3/5Y-4.53% 8.01%
EPS Y/Y TTM-45.45%
Sales Y/Y TTM-23.90%
EPS Q/Q-109.25%
Sales Q/Q-23.76%
EarningsSep 17 BMO
EPS/Sales Surpr.- -

Ownership

Insider Own1.82%
Insider Trans-94.39%
Inst Own2.23%
Inst Trans75.40%
ROA-4.99%
ROE-
ROIC-
Gross Margin5.73%
Oper. Margin-0.52%
Profit Margin-1.02%
SMA20-1.94%
SMA50-8.72%
SMA200-40.97%
Trades-

Technical

Shs Outstand5.19M
Shs Float5.09M
Short Float0.26%
Short Ratio0.86
Short Interest0.01M
52W High11.17 -73.59%
52W Low2.48 18.95%
Volatility1.62% 4.12%
ATR (14)0.15
RSI (14)42.14
Beta0.74
Rel Volume0.00
Avg Volume15.31K
Volume0

Performance

Perf Week-2.32%
Perf Month-5.14%
Perf Quarter-21.96%
Perf Half Y-51.40%
Perf YTD15.23%
Perf Year-28.23%
Perf 3Y-87.15%
Perf 5Y-94.15%
Perf 10Y-
Recom1.00
Target Price12.01
Prev Close2.95
Price2.95
Change %0.00%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Apr 15, 2021ResumedCCitigroupBuy$16+442.4%

Peers

Mkt cap
TickerCompanyMkt cap
POMPomdoctor Ltd12.84M
RDGTRidgetech Inc4.07M
HKPDCellyan Biotechnology Co Ltd3.88M
MEDSDataMEDS AI Inc4.12M
CORCencora Inc65.98B
MCKMckesson Corp124.03B
AHGAkso Health Group ADR1.07B
UPCUniverse Pharmaceuticals INC7.64M
CPHIChina Pharma Holdings Inc24.79M
SYSo-Young International Inc ADR170.87M

Insider trading

latest 14 of 37
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Chen Yang LukeDirectorJun 12 '26Sale0.2349,92011,482539,462Sep 29 06:57 AM
Chen Yang LukeDirectorJun 15 '26Sale0.2344,00010,120495,462Sep 29 06:57 AM
Chen Yang LukeDirectorSep 23 '26Sale0.1844,0007,920451,462Sep 29 06:57 AM
Chen Yang LukeDirectorSep 28 '26Sale0.1838,1206,862413,342Sep 29 06:57 AM
Chen Yang LukeDirectorMay 27 '26Sale0.253,400850589,382Sep 29 06:57 AM
Chen Yang LukeDirectorMay 26 '26Sale0.271,440389592,782Sep 29 06:57 AM
Chen Yang LukeDirectorJun 12 '26Sale0.2349,92011,482539,462Sep 24 06:10 AM
Chen Yang LukeDirectorJun 15 '26Sale0.2344,00010,120495,462Sep 24 06:10 AM
Chen Yang LukeDirectorSep 23 '26Sale0.1844,0007,920451,462Sep 24 06:10 AM
Chen Yang LukeDirectorMay 27 '26Sale0.253,400850589,382Sep 24 06:10 AM
Chen Yang LukeDirectorMay 26 '26Sale0.271,440389592,782Sep 24 06:10 AM
Chen Yang LukeDirectorJun 12 '26Sale0.2349,92011,482539,462Jun 16 06:21 AM
Chen Yang LukeDirectorJun 15 '26Sale0.2344,00010,120495,462Jun 16 06:21 AM
Chen Yang LukeDirectorMay 27 '26Sale0.253,400850589,382Jun 16 06:21 AM

News

latest 14 of 206
  • 111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee (PR Newswire)
  • 111, Inc. Announces Establishment of the Special Committee (PR Newswire)
  • 111 Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the Company (PR Newswire)
  • 111, Inc. Announces Second Quarter 2026 Unaudited Financial Results (PR Newswire)
  • 111, Inc. Announces First Quarter 2026 Unaudited Financial Results (PR Newswire) -10.27%
  • Loading…
  • 111, Inc. Announces Fourth Quarter and Fiscal Year 2025 Financial Results (PR Newswire)
  • 111, Inc. Announces Third Quarter 2025 Unaudited Financial Results (PR Newswire)
  • 111, Inc. Announces Second Quarter 2025 Unaudited Financial Results (PR Newswire) -6.24%
  • 111, Inc. Announces First Quarter 2025 Unaudited Financial Results (PR Newswire)
  • 111 Inc (YI) Q4 2024 Earnings Call Highlights: Navigating Challenges with Strategic Efficiency (GuruFocus.com) +9.40%
  • 111, Inc. (YI) Q4 2024 Earnings Call Transcript (SeekingAlpha) -7.82%
  • 111, Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results (PR Newswire)
  • 111, Inc. to Participate in Fireside Chat with Water Tower Research on March 26, 2025 (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-09-17-0.656--0.656342.84--
2026Q12026-06-04-0.610--0.608343.1--
2025Q42026-04-09-0.263--0.261412.76--
2025Q32025-12-17-0.198--0.208425.24--
2025Q22025-09-17-0.309--0.311450.6--
2025Q12025-06-19-0.278--0.280490.9530.61-
2024Q42025-03-20-0.030--0.320532.14541.62-
2024Q32024-11-27-0.276--0.278496.5503.56-
2024Q22024-08-29-0.225--0.226480.59478.77-
2023Q22023-08-24-0.947--0.971484.3--
2023Q12023-06-15-0.531--0.555516.3--
2022Q42023-03-23-2.005--1.927602.65--
2022Q32022-12-01-1.633--1.709471.44--
2022Q22022-08-25-1.662--1.740442.78--
2022Q12022-06-16-1.965--2.087444.01--
2021Q42022-03-17-2.109--2.097544.66--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-11.391-6.348-11.552266.29262.11
2019FY-8.733-3.323-8.835565.78-
2020FY-8.520-3.545-8.0281,262-
2021FY-12.728-6.061-12.5231,9571,973
2022FY-7.267--7.4311,964-
2024FY-0.105--1.0471,9921,986
2025FY-1.112--1.1121,838-

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026FYS2025-06-281002,3922,3922,392
2026FYS2025-06-271002,3922,3922,392
2026FYS2025-06-261002,3922,3922,392
2026FYS2025-06-251002,3922,3922,392
2026FYS2025-06-241002,3922,3922,392
2026FYS2025-06-231002,3922,3922,392
2026FYS2025-06-221002,3922,3922,392
2026FYS2025-06-211002,3922,3922,392
2026FYS2025-06-201002,3922,3922,392
2026FYS2025-06-191002,3922,3922,392
2026FYS2025-06-181002,3922,3922,392
2026FYS2025-06-171002,3922,3922,392
2026FYS2025-06-161002,3922,3922,392
2026FYS2025-06-151002,3922,3922,392

Estimate history

EPS, annual-4.496-11.552-8.835-8.028-12.523-7.431-6.575-1.047-1.062-1.729
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.226-0.278-0.32-0.28-0.311-0.208-0.261-0.608-0.652
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual141.973269.906571.9441188.4781926.6882007.3172109.8192001.0581746.6951495.96
Period201720182019202020212022202320242025TTM
Sales, quarterly472.842502.347535.218485.009443.191419.253397.74341.058337.904
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual4.5814.5544.6064.6684.7074.7524.9525.0445.1855.185
Period201720182019202020212022202320242025MRQ
Shares, quarterly4.9664.9665.0445.0445.0445.0445.1855.1855.185
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1,495.961,746.692,001.062,109.822,007.321,926.691,188.48571.94269.91
Cost of Goods Sold Incl. D&A1,410.201,646.061,885.841,989.991,882.581,830.381,135.48548.04254.15
Gross Profit85.75100.63115.22119.83124.7496.3053.0023.9115.76
Selling, General and Administrative Excl. Other93.48102.07116.09169.01178.86196.18122.6994.7976.16
Research and Development9.098.409.6817.5520.7229.3513.348.9610.77
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-7.73-1.43-0.87-49.19-54.12-99.88-69.69-70.88-60.41
Interest Expense5.024.953.942.842.000.851.280.520.00
Unusual Expense0.000.000.000.000.000.000.00--
Net Income Before Taxes-9.64-3.13-2.87-49.85-55.85-96.29-67.67-72.62-57.73
Income Taxes0.000.000.010.040.000.000.000.000.00
Consolidated Net Income-16.35-9.96-10.44-49.88-55.85-96.29-67.67-72.62-57.74
Net Income From Continuing Operations-15.20-9.24-9.00-55.43-61.91-103.86-66.14-72.30-57.44
Net Income-15.20-9.24-9.00-55.43-61.91-103.86-66.14-72.30-57.44
EPS (Recurring)-1.72-1.06-1.05-6.57-7.43-12.52-8.03-8.84-11.55
EPS (Basic, Before Extraordinaries)-1.73-1.06-1.05-6.57-7.43-12.52-8.03-8.84-11.55
EPS (Diluted)-1.73-1.06-1.05-6.57-7.43-12.52-8.03-8.84-11.55
EBITDA-0.211.49-46.11-48.06-95.66-67.66-69.19-58.70
Non-Operating Income (Expense)3.113.251.932.180.274.443.29-1.222.67
Other After Tax Adjustments-6.71-6.83-7.550.000.000.000.000.000.00
Stock Option Compensation Expense0.971.102.2131.9223.3716.938.235.895.82
Price To Sales Ratio0.030.010.030.060.130.150.480.961.13
Gross Margin5.735.765.765.686.215.004.464.185.84
Operating Margin-0.52-0.08-0.04-2.33-2.70-5.18-5.86-12.39-22.38
Net Margin-1.02-0.53-0.45-2.63-3.08-5.39-5.57-12.64-21.28
Shares Outstanding5.195.195.044.954.754.714.674.614.55
Market Capitalization15.3015.3031.4273.65142.76164.76324.40309.98279.64

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue337.90341.06397.74419.25443.19485.01535.22502.35
Cost of Goods Sold Incl. D&A318.47322.87374.48394.38417.56458.20507.05472.96
Gross Profit19.4318.1923.2624.8725.6326.8128.1629.38
Selling, General and Administrative Excl. Other23.2621.1223.9225.1826.0826.8430.0829.14
Research and Development2.802.082.082.142.062.122.142.45
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.83-2.93-0.66-0.30-0.45-0.02-1.910.25
Interest Expense1.311.131.600.991.171.200.731.09
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-4.65-3.87-0.92-0.20-1.00-1.00-1.74-0.48
Income Taxes0.000.000.000.00-0.000.000.000.00
Consolidated Net Income-6.18-5.70-2.36-2.10-2.76-2.73-4.10-2.57
Net Income From Continuing Operations-5.75-5.35-2.29-1.81-2.70-2.43-2.76-2.39
Net Income-5.75-5.35-2.29-1.81-2.70-2.43-2.76-2.39
EPS (Recurring)-0.65-0.61-0.26-0.21-0.31-0.28-0.32-0.28
EPS (Basic, Before Extraordinaries)-0.65-0.61-0.26-0.21-0.31-0.28-0.32-0.28
EPS (Diluted)-0.65-0.61-0.26-0.21-0.31-0.28-0.32-0.28
Non-Operating Income (Expense)0.480.201.351.090.610.220.900.36
Other After Tax Adjustments-1.53-1.83-1.45-1.90-1.75-1.72-2.36-2.08
Stock Option Compensation Expense0.400.160.060.350.400.570.550.79
Price To Sales Ratio0.030.040.010.020.030.040.030.03
Gross Margin5.755.335.855.935.785.535.265.85
Operating Margin-1.13-0.86-0.17-0.07-0.10-0.01-0.360.05
Net Margin-1.70-1.57-0.58-0.43-0.61-0.50-0.52-0.48
Shares Outstanding5.195.195.195.045.045.045.044.97
Market Capitalization15.3032.8912.9122.9536.0240.2831.4237.55

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments87.4871.0194.99132.72148.00247.52100.17161.1770.82
Short Term Receivables62.2486.41109.49103.62104.3467.2437.2623.3714.66
Inventories144.85192.60202.56223.60179.21118.7271.9431.1922.77
Other Current Assets9.5012.996.565.538.065.793.313.783.92
Total Current Assets304.07363.00413.60465.47439.60439.26212.68219.51112.17
Net Property, Plant & Equipment9.3316.7119.4830.5549.2821.7216.902.962.61
Total Investments and Advances0.000.000.280.290.470.020.021.621.71
Long-Term Note Receivable-------0.0043.00
Intangible Assets0.120.200.320.470.771.001.150.660.73
Other Assets1.332.011.882.933.470.770.430.490.00
Total Assets314.85381.92435.55499.71493.59462.78231.17225.24160.23
Short Term Debt Incl. Current Port. of LT Debt29.5932.1661.4235.0651.0640.8218.110.000.00
Accounts Payable183.51235.84224.01253.87211.40164.1363.7930.9219.68
Income Tax Payable0.410.580.985.431.72---0.22
Other Current Liabilities66.0652.36100.6597.6570.0244.2529.1314.8910.99
Total Current Liabilities279.57320.93387.05392.01334.20249.20111.0345.8130.89
Long Term Debt4.297.608.8314.4525.999.548.180.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.311.230.740.000.240.570.851.180.00
Total Liabilities284.17329.76396.62406.46360.43259.31120.0747.0030.89
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00274.07
Common Equity-100.49-88.04-82.27-59.64-27.1954.65111.50178.32-144.95
Total Shareholders Equity-100.49-88.04-82.27-59.64-27.1954.65111.50178.32129.12
Accumulated Minority Interest131.17140.21121.20152.89160.36148.82-0.39-0.070.22
Total Equity30.6852.1638.9393.25133.16203.47111.10178.24129.34
Total Liabilities & Stockholders Equity314.85381.92435.55499.71493.59462.78231.17225.24160.23
Book Value Per Share-11.44-10.19-9.62-7.14-3.276.6113.5921.87-17.72
Tangible Book Value Per Share-19.40-17.49-16.68-12.65-5.9411.4923.9639.01-31.80
Full-Time Employees1,0631,2381,5201,6572,1142,1891,9321,350-
Price to Book Ratio-0.23-0.61-1.84-4.81-10.6910.514.952.812.54
Return on Assets-2.65-2.20-11.85-12.47-21.72-19.06-31.68-29.80-21.44
Return on Equity-----756.53-79.62-49.90-37.37-25.64
Return on Invested Capital------103.04-60.41-32.21-28.49
Quick Ratio0.570.530.550.620.781.291.274.112.89
Current Ratio1.091.131.071.191.321.761.924.793.63

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income--3.13-2.89-49.88-55.85-96.29-67.67-72.62-57.74
Depreciation-1.652.363.076.064.222.031.691.70
Other Funds (Non Cash)-7.3210.3043.5839.7542.6219.168.176.29
Funds from Operations-5.839.78-3.23-10.04-49.46-46.49-59.09-49.75
Extraordinary Item-0.000.000.000.000.000.000.000.00
Changes in Working Capital-10.7426.77-59.896.60-57.3529.57-15.06-2.09
Cash from Operating Activities-5.5416.5736.55-63.13-3.44-106.81-16.92-74.15-51.84
Capital Expenditures0.00-0.62-2.11-1.39-4.71-9.72-3.74-3.56-2.24
Net Assets From Acquisitions--0.70-1.880.000.000.000.00-0.00
Sale of Fixed Assets and Businesses0.010.010.230.230.180.05140.170.030.02
Purchase or Sale of Investments--6.877.2422.57-2.0419.00-43.3237.938.94
Purchase of Investments--104.33-63.92-129.05-188.44-284.59-72.44-86.98-78.46
Sale Or Maturity of Investments-97.4771.16151.62186.41303.5929.12124.9187.40
Other Uses-0.000.000.00-0.440.000.000.000.00
Other Sources0.000.000.000.000.000.000.00-0.00
Cash from Investing Activities-8.96-8.173.4821.42-7.019.3293.1134.406.72
Cash Dividends Paid-0.000.000.000.000.000.00-0.00
Change in Capital Stock-0.10-12.160.030.04-0.46-0.82-1.69105.01
Repurchase of Common Pref Stock-0.00-12.160.000.00-0.91-1.74-3.330.00
Sale of Common Pref Stock-0.100.000.030.040.450.921.64105.01
Proceedsfrom Stock Options0.000.000.000.000.000.000.921.64105.01
Issuance or Reduction of Debt, Net-3.71-24.6123.92-11.984.7119.4413.760.00
Change in Long Term Debt-0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt-0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt-0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-6.05-6.06-17.975.1215.327.27-3.683.7041.99
Other Financing Activities Uses-13.48-13.50-116.76-199.73-80.68-2.33-3.680.000.00
Cash from Financing Activities-13.67-2.25-54.7429.073.3811.5314.9415.77147.00
Exchange Rate Effect-0.15-0.170.09-0.530.55-0.54-1.181.401.81
Net Change in Cash-28.325.98-14.62-13.16-6.52-86.5089.94-22.58103.68
Free Cash Flow-15.9534.43-64.51-8.13-116.51-20.61-77.05-54.02
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow-1.401.55------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments56.1757.4187.4878.3271.6176.79
Short Term Receivables38.0038.1262.2450.3447.8849.83
Inventories132.15147.14144.85176.16178.39185.17
Other Current Assets27.6326.849.5030.7032.3530.92
Total Current Assets253.94269.50304.07335.52330.23342.71
Net Property, Plant & Equipment8.449.119.3311.4413.6014.80
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.110.110.120.140.160.17
Other Assets1.151.351.331.621.631.95
Total Assets263.64280.08314.85348.73345.61359.62
Short Term Debt Incl. Current Port. of LT Debt38.3237.2929.5923.8823.7220.48
Accounts Payable159.76175.52183.51217.79216.91231.69
Income Tax Payable--0.41---
Other Current Liabilities38.5035.9166.0671.1352.7247.72
Total Current Liabilities236.57248.72279.57312.80293.35299.89
Long Term Debt3.243.814.294.885.996.44
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.320.320.310.311.211.19
Total Liabilities240.13252.84284.17317.99300.55307.52
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-114.40-106.94-100.49-96.07-93.93-90.50
Total Shareholders Equity-114.40-106.94-100.49-96.07-93.93-90.50
Accumulated Minority Interest137.91134.17131.17126.81138.99142.61
Total Equity23.5027.2330.6830.7445.0652.11
Total Liabilities & Stockholders Equity263.64280.08314.85348.73345.61359.62
Book Value Per Share-13.02-12.17-11.44-11.11-10.87-10.47
Tangible Book Value Per Share-22.08-20.65-19.40-19.08-18.65-17.98
Full-Time Employees--1,063---
Price to Book Ratio-0.23-0.59-0.23-0.42-0.40-0.77
Return on Assets-4.99-3.80-2.65-2.49-2.82-2.49
Quick Ratio0.510.490.570.510.520.53
Current Ratio1.071.081.091.071.131.14

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Extraordinary Item--0.000.000.000.00
Cash from Operating Activities-1.79-13.254.185.32-8.4015.45
Capital Expenditures0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.010.000.000.00
Other Uses--0.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-5.924.24-3.13-4.15-0.03-0.15
Cash Dividends Paid-----0.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.00---0.00
Repurchase of Common Pref Stock-0.00---0.00
Sale of Common Pref Stock-----0.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-----0.00
Change in Long Term Debt-----0.00
Issuance of Long Term Debt-----0.00
Reduction of Long Term Debt-----0.00
Net Financing Active Other Cash Flow0.000.00-6.050.000.000.00
Other Financing Activities Uses0.000.00-13.480.000.000.00
Cash from Financing Activities-0.59-17.623.670.862.54-10.02
Exchange Rate Effect-0.04-0.05-0.03-0.03-0.11-0.00
Net Change in Cash-8.33-26.684.692.00-6.005.28

Revenue breakdown

Drugs2024: 1.86B 2025: 1.62B
Marketplace Service2024: 9.12M 2025: 7.90M
Medical Supplies And Devices2024: 20.08M 2025: 21.20M
Nutritional Supplements2024: 76.60M 2025: 60.48M
Other Products2024: 28.08M 2025: 32.52M
Recommendation service and other2024: 5.70M 2025: 3.98M
China2024: 2.00B 2025: 1.75B
Business To Business2024: 1.97B 2025: 1.71B
Business To Consumer2024: 38.70M 2025: 32.67M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.26%0.0M5.1M14.23K
2026-10-150.08%0.0M5.1M11.57K
2026-09-300.14%0.0M5.1M12.40K
2026-09-150.21%0.0M5.1M16.35K
2026-08-310.19%0.0M5.1M20.39K
2026-08-140.13%0.0M5.1M21.49K
2026-07-310.16%0.0M5.1M23.19K
2026-07-150.18%0.0M5.1M24.47K
2026-06-300.09%0.0M5.1M22.73K
2026-06-150.10%0.0M5.1M17.69K
2026-05-290.12%0.0M5.1M14.22K
2026-05-150.28%0.0M5.1M14.09K
2026-04-300.27%0.0M5.1M21.82K
2026-04-150.51%0.0M5.0M29.82K
2026-03-310.58%0.0M5.0M47.22K
2026-03-130.50%0.0M5.0M47.11K
2026-02-270.50%0.0M5.0M45.73K
2026-02-130.52%0.0M5.0M45.00K
2026-01-300.79%0.0M5.0M35.86K
2026-01-150.72%0.0M5.0M27.49K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-26SEC
2026-09-294Statement of changes in beneficial ownership of securities2026-09-28SEC
2026-09-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-28SEC
2026-09-244Statement of changes in beneficial ownership of securities2026-09-23SEC
2026-09-17SCHEDULE 13DSEC
2026-09-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-17SEC
2026-09-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-17SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-09144Filing for proposed sale of securities under Rule 144.SEC
2026-06-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-04SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-26SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-26SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-26SEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-04-3020-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-04-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-09SEC
2026-03-203Initial statement of beneficial ownership of securities2026-03-20SEC
2026-03-203Initial statement of beneficial ownership of securities2026-03-20SEC
2026-03-203Initial statement of beneficial ownership of securities2026-03-20SEC
2026-03-193Initial statement of beneficial ownership of securities2026-03-19SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2026-03-183Initial statement of beneficial ownership of securities2026-03-18SEC
2025-12-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-12-17SEC
2025-09-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-09-17SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090022.70K3
2026-080000
2026-070000
2026-0600213.91K15
2026-0500132.53K18
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
CITADEL ADVISORS LLC0.33%
RENAISSANCE TECHNOLOGIES LLC0.25%
Serenus Wealth Advisors, LLC0.08%
UBS Group AG0.03%
Nuveen, LLC0.01%
CITIGROUP INC0.01%
SBI Securities Co., Ltd.0.00%
MORGAN STANLEY0.00%
JPMORGAN CHASE & CO0.00%
RHUMBLINE ADVISERS0.00%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.05%
Avantis Emerging Markets ex-China Equity ETF0.00%

OakChart. YI. Cached 15 minutes.